2-m-tolyl-4-(3-chlorobenzyl)-1,2,4-thiadiazolidine-3,5-dione | 1352552-38-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-m-tolyl-4-(3-chlorobenzyl)-1,2,4-thiadiazolidine-3,5-dione
• 英文别名: 4-[(3-Chlorophenyl)methyl]-2-(3-methylphenyl)-1,2,4-thiadiazolidine-3,5-dione；4-[(3-chlorophenyl)methyl]-2-(3-methylphenyl)-1,2,4-thiadiazolidine-3,5-dione
• CAS: 1352552-38-5
• 化学式: C₁₆H₁₃ClN₂O₂S
• 分子量: 332.81
• InChiKey: RKIFXQWYQPFKGV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  22
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  65.9
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  异硫氰酸3-氯苄酯 、 异氰酸间甲苯酯 在 磺酰氯 、 氧气 作用下， 以 四氢呋喃 为溶剂， 反应 18.5h， 以59%的产率得到2-m-tolyl-4-(3-chlorobenzyl)-1,2,4-thiadiazolidine-3,5-dione
  参考文献：
  名称：

  Small Molecule Inhibitors of Regulators of G Protein Signaling (RGS) Proteins

  摘要：

  Recently, regulators of G protein signaling (RGS) proteins have emerged as potential therapeutic targets since they provide an alternative method of modulating the activity of G protein-coupled receptors, the target of so many drugs. Inhibitors of RGS proteins must block a protein protein interaction (RGS-G alpha) but also be cell and, depending on the therapeutic target, blood brain barrier permeable. A lead compound (la) was identified as an inhibitor of RGS4 in a screening assay, and this has now been optimized for activity, selectivity, and solubility. The newly developed ligands (11b and 13) display substantial selectivity over the closely related RGS8 protein, lack the off-target calcium mobilization activity of the lead la, and have excellent aqueous solubility. They are currently being evaluated in vivo in rodent models of depression.

  DOI：

  10.1021/ml200263y

文献信息

• SMALL MOLECULE INHIBITORS OF RGS PROTEINS
  申请人：Neubig Richard

  公开号：US20120277273A1

  公开（公告）日：2012-11-01

  The invention relates to compositions having RGS (regulator of G-protein Signaling) inhibiting activity, and methods of use thereof. In some embodiments, RGS-inhibiting compositions find use in research on or treatment of disease states (e.g., diabetes, epilepsy, neuropathic pain, depression and other diseases).

  该发明涉及具有RGS（G蛋白信号调节因子）抑制活性的组合物，以及其使用方法。在某些实施例中，具有RGS抑制活性的组合物可用于研究或治疗疾病状态（例如糖尿病、癫痫、神经痛、抑郁症和其他疾病）。
• Imidazole Derivatives as IDO Inhibitors
  申请人：Mautino Mario R.

  公开号：US20120277217A1

  公开（公告）日：2012-11-01

  Presently provided are IDO inhibitors of general formulae (VII), (VIII) as shown below and pharmaceutical compositions thereof, useful for modulating an activity of indoleamine 2,3-dioxygenase; treating indoleamine 2,3-dioxygenase (IDO) mediated immunosuppression; treating a medical conditions that benefit from the inhibition of enzymatic activity of indoleamine-2,3-dioxygenase; enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent; treating tumor-specific immunosuppression associated with cancer; and treating immunosupression associated with an infectious disease.

  目前提供的是通式（VII），（VIII）所示的IDO抑制剂及其制药组合物，用于调节吲哚胺2,3-二氧化酶的活性；治疗由吲哚胺2,3-二氧化酶（IDO）介导的免疫抑制；治疗受益于抑制吲哚胺2,3-二氧化酶酶活性的医疗状况；增强包括给予抗癌药物在内的抗癌治疗的有效性；治疗与癌症相关的肿瘤特异性免疫抑制；以及治疗与传染病相关的免疫抑制。
• IMIDAZOLE DERIVATIVES AS IDO INHIBITORS
  申请人：Newlink Genetics Corporation

  公开号：EP2493862B1

  公开（公告）日：2016-10-05
• US8722720B2
  申请人：——

  公开号：US8722720B2

  公开（公告）日：2014-05-13
• US8865750B2
  申请人：——

  公开号：US8865750B2

  公开（公告）日：2014-10-21